[
    [
        {
            "time": "2018-01-02",
            "original_text": "Blue-Chip Stocks to Buy for an Earnings Bump",
            "features": {
                "keywords": [
                    "earnings bump",
                    "blue-chip"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Blue-Chip Stocks to Buy for an Earnings Bump",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know",
            "features": {
                "keywords": [
                    "dips",
                    "broader markets"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AbbVie Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 20, 2018 – ABBV",
            "features": {
                "keywords": [
                    "class action lawsuit",
                    "shareholders"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "legal",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AbbVie Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 20, 2018 – ABBV",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 4,
                "Headline_Structure": 9,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "ABBVIE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In AbbVie, Inc. To Contact The Firm",
            "features": {
                "keywords": [
                    "lead plaintiff deadline",
                    "losses"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "legal",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "ABBVIE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In AbbVie, Inc. To Contact The Firm",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 4,
                "Headline_Structure": 9,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",
            "features": {
                "keywords": [
                    "class action lawsuit",
                    "investor alert"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "legal",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 4,
                "Headline_Structure": 9,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "AbbVie Becomes Oversold (ABBV)",
            "features": {
                "keywords": [
                    "oversold"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie Becomes Oversold (ABBV)",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "Insiders Buy the Holdings of DLN ETF",
            "features": {
                "keywords": [
                    "insider buying",
                    "ETF"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Insiders Buy the Holdings of DLN ETF",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-09",
            "original_text": "AbbVie rheumatoid arthritis drug succeeds in late stage trial",
            "features": {
                "keywords": [
                    "rheumatoid arthritis",
                    "drug succeeds",
                    "trial"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie rheumatoid arthritis drug succeeds in late stage trial",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-10",
            "original_text": "Biogen (BIIB) Q3 Earnings & Sales Beat, Spinraza Shines",
            "features": {
                "keywords": [
                    "Q3 earnings",
                    "sales beat",
                    "Spinraza"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Biogen (BIIB) Q3 Earnings & Sales Beat, Spinraza Shines",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-11",
            "original_text": "AbbVie's Upadacitinib Shows Significant Improvements in Physical Function, Pain and Quality of Life as a Monotherapy in Patients with Rheumatoid Arthritis in Phase 3 Patient-Reported Outcomes Data",
            "features": {
                "keywords": [
                    "Upadacitinib",
                    "Phase 3",
                    "patient-reported outcomes"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie's Upadacitinib Shows Significant Improvements in Physical Function, Pain and Quality of Life as a Monotherapy in Patients with Rheumatoid Arthritis in Phase 3 Patient-Reported Outcomes Data",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-12",
            "original_text": "The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares",
            "features": {
                "keywords": [
                    "pre-clinical data",
                    "earnings",
                    "shares"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-13",
            "original_text": "Today's Research Reports on Trending Tickers: AbbVie and Endo International",
            "features": {
                "keywords": [
                    "research reports",
                    "trending tickers"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Today's Research Reports on Trending Tickers: AbbVie and Endo International",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-14",
            "original_text": "Validea Joel Greenblatt Strategy Daily Upgrade Report - 10/23/2018",
            "features": {
                "keywords": [
                    "Greenblatt strategy",
                    "upgrade report"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Validea Joel Greenblatt Strategy Daily Upgrade Report - 10/23/2018",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-01-15",
            "original_text": "ABBV ACHIEVES Goals, HealthStream's CFO Resigns, NTEC On Watch",
            "features": {
                "keywords": [
                    "ACHIEVES goals",
                    "CFO resigns"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "management"
                ],
                "causal_factor": "true",
                "causal_impact": "mixed",
                "affected_by_time_series": "true",
                "ts_effect_direction": "mixed"
            },
            "scores": {
                "News_content": "ABBV ACHIEVES Goals, HealthStream's CFO Resigns, NTEC On Watch",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-16",
            "original_text": "SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline - ABBV",
            "features": {
                "keywords": [
                    "shareholder alert",
                    "class action lawsuit"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "legal",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline - ABBV",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 4,
                "Headline_Structure": 9,
                "Source_Recency": 3
            }
        }
    ]
]